B. Baker

发表

Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies.

D. Spector, P. Lorenz, B. Baker, 1998, Molecular biology of the cell.

Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents

C. F. Bennett, S. Crooke, N. Dean, 2003, The Journal of Biological Chemistry.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

S. Solomon, A. Shah, W. Litchy, 2018, The New England journal of medicine.

Novel mechanisms for antisense-mediated regulation of gene expression.

B. Monia, B. Baker, 1999, Biochimica et biophysica acta.

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

J. Jukema, E. Sijbrands, M. Trip, 2010, Journal of the American College of Cardiology.

Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia

M. Graham, R. Crooke, B. Baker, 2015 .

Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes

S. Bhanot, B. Baker, R. Geary, 2018, Diabetes Care.

Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteers Peripheral Blood Mononuclear Cells

S. Henry, B. Baker, T. Machemer, 2021, bioRxiv.

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B

S. Crooke, B. Baker, R. Geary, 2015, Clinical Pharmacokinetics.

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

M. Benson, Shuling Guo, B. Monia, 2020, ESC heart failure.

2′-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells*

E. Lesnik, C. F. Bennett, B. Baker, 1997, The Journal of Biological Chemistry.

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

S. Bhanot, B. Baker, R. Geary, 2020, The lancet. Gastroenterology & hepatology.

Targeting APOC3 in the familial chylomicronemia syndrome.

D. Gaudet, D. Brisson, K. Tremblay, 2014, The New England journal of medicine.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Richard G. Lee, S. Crooke, M. Graham, 2013, Circulation research.

Improvements in the Tolerability Profile of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods

S. Bhanot, B. Baker, R. Geary, 2021, Nucleic acid therapeutics.

Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-α in Two Murine Models of Colitis

K. Myers, B. Baker, K. Madsen, 2003, Journal of Pharmacology and Experimental Therapeutics.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

J. Witztum, M. Graham, R. Crooke, 2015, The Lancet.

Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma.

A. Levin, B. Baker, R. Yu, 2002, Analytical biochemistry.

Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α

B. Baker, R. Yu, R. Geary, 2002, Journal of Pharmacology and Experimental Therapeutics.

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy

S. Bhanot, M. Krebs, B. Baker, 2019, Diabetes Care.

Decapitation of a 5' capped RNA by an antisense copper complex conjugate

B. Baker, J. Kiely, K. Ramasamy, 1996 .

Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element.

P. D. Cook, D. Ecker, B. Baker, 1991, Nucleic acids research.

Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis.

K. Myers, B. Baker, K. Madsen, 2003, The Journal of pharmacology and experimental therapeutics.

A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice.

M. Waters, B. Baker, C. Wraight, 2006, The Journal of endocrinology.

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

D. Gaudet, J. Kastelein, D. Brisson, 2015, The New England journal of medicine.

Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience

S. Crooke, B. Baker, R. Yu, 2019, Nucleic acid therapeutics.

CLEAVAGE OF THE 5'CAP STRUCTURE OF MRNA BY A EUROPIUM(III) MACROCYCLIC COMPLEX WITH PENDANT ALCOHOL GROUPS

J. Morrow, B. Baker, Ning Wei, 1997 .

Cardiovascular Therapeutic Applications

R. Crooke, B. Baker, M. Wedel, 2007 .

Modulation of eucaryotic initiation factor-4E binding to 5'-capped oligoribonucleotides by modified anti-sense oligonucleotides.

L. Miraglia, C. Hagedorn, B. Baker, 1992, The Journal of biological chemistry.

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials

S. Crooke, S. Bhanot, Nelson Salgado, 2017, Nucleic acid therapeutics.

Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis

B. Baker, R. Geary, J. Matson, 2006, Alimentary pharmacology & therapeutics.

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.

F. Akdim, D. Tribble, Joann D Flaim, 2010, The American journal of cardiology.

Liver‐directed drugs for transthyretin‐mediated amyloidosis

M. Maurer, B. Baker, M. Fontana, 2022, Journal of the peripheral nervous system : JPNS.

Oligonucleotide-europium complex conjugate designed to cleave the 5' cap structure of the ICAM-1 transcript potentiates antisense activity in cells.

L. Chappell, B. Baker, A. Siwkowski, 1999, Nucleic acids research.

Synthesis of 2'-deoxyguanosine containing a N2-polyamine

P. D. Cook, B. Baker, F. Bakir, 1993 .

Sequence-specific cleavage of DNA by N-bromoacetyldistamycin. Product and kinetic analyses

P. Dervan, B. Baker, 1989 .

Pharmacology of Antisense Drugs.

B. Baker, C. Bennett, R. Geary, 2017, Annual review of pharmacology and toxicology.

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers

Christopher E. Hart, H. Bui, S. Crooke, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Richard G. Lee, S. Bhanot, M. Graham, 2016, Diabetes Care.

Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics

Mark J. Graham, Richard G. Lee, M. Graham, 2013, Journal of Cardiovascular Translational Research.

Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B

J. Kastelein, M. Graham, R. Crooke, 2006, Circulation.

Discovery and analysis of antisense oligonucleotide activity in cell culture.

B. Monia, E. Koller, B. Baker, 2001, Methods.

RNA-Targeted Therapeutics.

S. Crooke, J. Witztum, B. Baker, 2018, Cell metabolism.

Positional effect of chemical modifications on short interference RNA activity in mammalian cells.

R. Griffey, B. Baker, T. Vickers, 2005, Journal of Medicinal Chemistry.

Antisense technology: an overview and prospectus

S. Crooke, R. Crooke, B. Baker, 2021, Nature Reviews Drug Discovery.

Antisense technology: A review

S. Crooke, R. Crooke, B. Baker, 2021, The Journal of biological chemistry.

Antisense Drug Discovery and Development Technology Considered in a Pharmacological Context.

Stanley T Crooke, Xue-Hai Liang, Rosanne M Crooke, 2020, Biochemical pharmacology.

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon

Brenda F Baker, Adrian R Krainer, Y. Hua, 2007, PLoS biology.

Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity.

B. Baker, Bryan A. Kraynack, B. Kraynack, 2006, RNA.

A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans

M. Graham, R. Crooke, A. Szalai, 2012, Molecular therapy. Nucleic acids.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

Richard G. Lee, E. Hurh, M. Graham, 2017, The New England journal of medicine.

IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production

B. Monia, B. Baker, A. Macleod, 2019, Nucleic acid therapeutics.

Inhibition of Prekallikrein for Hereditary Angioedema.

J. Bernstein, W. Lumry, B. Baker, 2022, The New England journal of medicine.

The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans

S. Crooke, S. Bhanot, B. Baker, 2017, Nucleic acid therapeutics.

Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expression.

J. Pober, B. Monia, L. Madge, 2004, Molecular pharmacology.

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

J. Kastelein, M. Trip, A. Nederveen, 2012, European heart journal.

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.

F. Akdim, D. Tribble, Joann D Flaim, 2011, European heart journal.

Prevention and Epidemiology

J. Kastelein, M. Trip, A. Nederveen, 2022 .

ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes.

B. Baker, C. Bennett, T. Kishimoto, 2001, Antisense & nucleic acid drug development.

Effects of an Antisense Oligonucleotide Inhibitor of C‐Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers

P. Ridker, Joann D Flaim, E. Stroes, 2014, Journal of the American Heart Association.

mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis

W. Litchy, B. Baker, M. Polydefkis, 2020, Muscle & Nerve.

Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers

J. Kastelein, Joann D Flaim, B. Baker, 2014, Journal of the American Heart Association.

Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.

T. Misteli, D. Spector, P. Lorenz, 2000, Nucleic acids research.

Oligonucleotide conjugates of Eu(III) tetraazamacrocycles with pendent alcohol and amide groups promote sequence-specific RNA cleavage

L. Chappell, J. Morrow, B. Baker, 2000, JBIC Journal of Biological Inorganic Chemistry.

Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Richard G. Lee, S. Bhanot, M. Graham, 2016 .

Sequence Specific Cleavage of Double Helical DNA N-Bromoacetyldistamycin

P. Dervan, B. Baker, 1985 .

Treatment with mipomersen reduces levels of apoB-containing lipoproteins by increasing fractional removal of VLDL and LDL-apoB without reducing vldl-apob secretion

R. Morey, B. Baker, H. Ginsberg, 2014 .

Phase 1 Investigation of a Ligand-Conjugated Antisense Oligonucleotide with Increased Potency for the Treatment of Transthyretin Amyloidosis

Shuling Guo, B. Monia, B. Baker, 2019, Journal of Cardiac Failure.

RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cells.

B. Baker, T. P. Prakash, E. Swayze, 2006, Bioorganic & medicinal chemistry letters.

Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis

W. Litchy, B. Baker, C. Karam, 2020, Muscle & nerve.

Effects of Antisense Oligonucleotide-Mediated Depletion of Tumor Necrosis Factor (TNF) Receptor 1-Associated Death Domain Protein on TNF-Induced Gene Expression

J. Pober, B. Monia, L. Madge, 2004 .

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Richard G. Lee, S. Crooke, M. Graham, 2013, Circulation research.

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

M. Trip, F. Akdim, D. Tribble, 2010, Journal of the American College of Cardiology.

Abstract 16531: Decreased Cardiovascular Events in Familial Hypercholesterolemic Patients Treated With Mipomersen, an Antisense Inhibitor of Apolipoprotein B Translation

J. Kastelein, R. Santos, B. Baker, 2014 .

Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema.

E. Stroes, M. Levi, B. Baker, 2020, The New England journal of medicine.

Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-(cid:1) in Two Murine Models of Colitis

K. Myers, B. Baker, K. Madsen, 2002 .